ANNAPOLIS, Md., July 10 /PRNewswire-FirstCall/ -- PharmAthene, Inc.
(Amex: PIP) a biodefense company specializing in the development and
commercialization of medical countermeasures against chemical and
biological threats, announced today that Jordan P. Karp, J.D., has been
appointed Senior Vice President & General Counsel, overseeing all legal and
human resources matters for PharmAthene.
Mr. Karp joins PharmAthene with over 17 years of legal experience in a
variety of areas, including SEC compliance, corporate governance, mergers
and acquisitions, government and commercial contracting, and intellectual
property.
Prior to joining the Company, Mr. Karp was employed by Constellation
Energy Group, Inc., a diversified Fortune 125 energy company, from 2001 to
2007. From October 2002 to November 2007, Mr. Karp served as Vice President
& General Counsel for one of Constellation Energy's primary operating
divisions, Constellation NewEnergy, Inc., a leading retail marketer of
electricity and natural gas. Mr. Karp established and managed the legal
function for Constellation NewEnergy during a period of rapid growth, in
which annual revenues for Constellation's retail energy marketing segment
increased from $2.6 billion in 2003 to $9.1 billion in 2007.
Before his tenure at Constellation, Mr. Karp held in-house legal
positions of increasing responsibility at MCI Communications Corp.,
Guilford Pharmaceuticals Inc., and Mentor Technologies Group, Inc., where
Mr. Karp served as Vice President, General Counsel & Corporate Secretary.
Following a one year judicial clerkship on the U.S. Third Circuit Court of
Appeals, Mr. Karp started his legal career as an associate attorney with
the international law firm, Hogan & Hartson LLP, focusing on corporate and
securities matters.
Mr. Karp holds a B.A. in Natural Sciences from The Johns Hopkins
University and a J.D. from Yale Law School.
"Jordan brings a strong background in biopharmaceuticals in addition to
very specialized experience working with dynamic, growth-oriented
companies," said David P. Wright, President and Chief Executive Officer.
"These qualities are ideally suited to our mission at PharmAthene, and will
help us to advance our goal of becoming the leading provider of biodefense
therapeutics and prophylactic products for biological and chemical
terrorism with future expansion into broader markets."
About PharmAthene, Inc.
PharmAthene (Amex: PIP) was formed to meet the critical needs of the
United States and its allies by developing and commercializing medical
countermeasures against biological and chemical weapons. PharmAthene's lead
product development programs include (1) Valortim(TM) for the prevention
and treatment of anthrax infection, (2) Protexia(R) for the prevention and
treatment of morbidity and mortality associated with exposure to chemical
nerve agents, (3) a second generation recombinant protective antigen (rPA)
anthrax vaccine, (4) RypVax(TM) - a recombinant dual antigen vaccine for
plague, and (5) a third generation rPA anthrax vaccine. For more
information about PharmAthene, please visit http://www.PharmAthene.com.
Statement on Cautionary Factors
Except for the historical information presented herein, matters
discussed may constitute forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 that are subject to
certain risks and uncertainties that could cause actual results to differ
materially from any future results, performance or achievements expressed
or implied by such statements. Statements that are not historical facts,
including statements preceded by, followed by, or that include the words
"potential"; "believe"; "anticipate"; "intend"; "plan"; "expect";
"estimate"; "could"; "may"; "should"; or similar statements are
forward-looking statements. PharmAthene disclaims, however, any intent or
obligation to update these forward-looking statements. Risks and
uncertainties include risk associated with the reliability of the results
of the studies relating to human safety and possible adverse effects
resulting from the administration of the Company's product candidates,
unexpected funding delays and/or reductions or elimination of U.S.
government funding for one or more of the Company's development programs,
unforeseen safety issues, unexpected determinations that these product
candidates prove not to be effective and/or capable of being marketed as
products, as well as risks detailed from time to time in PharmAthene's
public disclosure filings with the U.S. Securities and Exchange Commission
(the "SEC"). There can be no assurance that such development efforts will
succeed or that other developed products will receive required regulatory
clearance, or that, even if such regulatory clearance were received, such
products would ultimately achieve commercial success. Copies of
PharmAthene's public disclosure filings are available from its investor
relations department.
SOURCE PharmAthene, Inc.
 back to top
Related links:
http://www.PharmAthene.com
CONTACT:
Stacey Jurchison of PharmAthene, Inc.,
+1-410-269-2610, cell +1-410-474-8200, JurchisonS@PharmAthene.com
|
